136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR)

Authors:
  • JMJ. Mazières
    J. Mazières

Abstract
No abstract available